Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 789 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SCD Clear all
Not listed Phase 1 Interventional

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

NCT02380079
View directory record Official record
Conditions
Sickle Cell Disease, Sickle-Beta Zero Thalassemia
Interventions
SCD-101
Drug
Lead sponsor
Invenux, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Combination of Hydroxyurea and Verapamil for Refractory Meningiomas

NCT00706810
View directory record Official record
Conditions
Cancer, Brain Cancer, Meningioma
Interventions
Hydroxyurea, Verapamil
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Phase 4 Interventional

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

NCT06665997
View directory record Official record
Conditions
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated No phase listed Observational

Kidney Transplantation in Patients With Sickle Cell Disease

NCT00663507
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 22, 2026, 9:38 AM EDT
Completed No phase listed Observational

Patient and Physician Survey Determinants of Appropriate ICD Utilization

NCT01514773
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Not listed
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 22, 2026, 9:38 AM EDT
Active, not recruiting Phase 2 Interventional

Reduced Intensity Transplantation for Severe Sickle Cell Disease

NCT04362293
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 25 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Results available

Actigraphy Improvement With Voxelotor (ActIVe) Study

NCT04400487
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Voxelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Farmington, Connecticut • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

NCT00236041
View directory record Official record
Conditions
Cancer, Breakthrough Pain
Interventions
ACTIQ®
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Effects of a Novel Machine Learning Mobile App on Diet Adherence in Individuals Following the Low Fodmap Diet

NCT04256551
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Heali mobile application + Registered Dietitian, Heali mobile application, Standard Dietary Education
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Not applicable Interventional

Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing

NCT07562451
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Music Therapy, Standard of Care
Other
Lead sponsor
Emory University
Other
Eligibility
8 Years to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Imatinib for Pain in Sickle Cell Anemia

NCT03997903
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Imatinib Mesylate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 25 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease

NCT02114203
View directory record Official record
Conditions
Phase 1 Sickle Cell
Interventions
PDE9i, placebo for PDE9i
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Chicago, Illinois • Boston, Massachusetts • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting No phase listed Observational

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

NCT05170412
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 120 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Not yet recruiting Phase 3 Interventional

Optimal Timing of Ketamine Initiation for SCD Pain

NCT07450430
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

NCT05632354
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Baton Rouge, Louisiana • New Orleans, Louisiana • Madison, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 1 Interventional

Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease

NCT00143572
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Magnesium Pidolate, Hydroxyurea
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 15 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

NCT01419977
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Placebo, Dalteparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional Results available

Hyperbaric Oxygen Therapy in Sickle Cell Pain

NCT03412045
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Interventions
hyperbaric oxygen therapy
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Phase 4 Interventional

Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease

NCT00252122
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Ketamine
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Oct 22, 2026, 9:38 AM EDT
Terminated Phase 2 Interventional

The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia

NCT05018728
View directory record Official record
Conditions
Sickle Cell Anemia in Children
Interventions
Voxelotor
Drug
Lead sponsor
Emory University
Other
Eligibility
4 Years to 30 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Not applicable Interventional

Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

NCT06374238
View directory record Official record
Conditions
Pain, Sickle Cell Disease
Interventions
CBT+ Health coach, CBT w/o Health Coach ( self-guided), Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years to 39 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Mobile, Alabama • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

NCT07252050
View directory record Official record
Conditions
Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant, Haploidentical Stem Cell Transplantation, Graft Failure
Interventions
Ruxolitinib
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
12 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Aurora, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 22, 2026, 9:38 AM EDT
Completed Not applicable Interventional

Use of Mobile Technology for Intensive Training in Medication Management

NCT02133560
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia
Interventions
Video recording, Medication Administration Log, Education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
5 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 22, 2026, 9:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

NCT03814746
View directory record Official record
Conditions
Sickle Cell Disease (SCD)
Interventions
Crizanlizumab (SEG101), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 9:38 AM EDT